Saudi Arabia In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  • 95 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
95
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Saudi Arabia In Vitro Diagnostics Market Outlook to 2018 -Clinical Chemistry Genetic Testing, Haematology, Histologyand Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureReport Details:Published:December 2012No. of Pages: 251Price: Single User License – US$2500Saudi Arabia In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureSummaryGlobalData’s new report, “Saudi Arabia In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture” provides key market data on the Saudi Arabia In VitroDiagnostics market. The report provides value (USD million), volume (units) and average price(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, MicrobiologyCulture and Genetic Testing. The report also provides company shares and distribution sharesdata for each of the aforementioned market categories. The report is supplemented with globalcorporate-level profiles of the key market participants with information on company financials andpipeline products, wherever available.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts.Scope- Market size and company share data for In Vitro Diagnostics market categories – ImmunoChemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology,Microbiology Culture and Genetic Testing.- Annualized market revenues (USD million), volume (units) and average price (USD) data for
  • 2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,forecast forward for 7 years to 2018.- 2011 company shares and distribution shares data for each of the market categories.- Global corporate-level profiles of key companies operating within the Saudi Arabia In VitroDiagnostics market.- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, AbbottLaboratories, Beckman Coulter, Inc., bioMerieux S.A., Becton, Dickinson and Company andothers.Reasons to buy- Develop business strategies by identifying the key market categories and segments poised forstrong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the Saudi Arabia In VitroDiagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected toregister strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of productdistribution – Identify, understand and capitalize.Get your copy of this report @http://www.reportsnreports.com/reports/213281-saudi-arabia-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-microbiology-culture.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 21.1 List of Tables 91.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In Saudi Arabia 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, Saudi Arabia, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, Saudi Arabia, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, Saudi Arabia, Company Share (2010-2011) 284 Clinical Chemistry In Saudi Arabia 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, Saudi Arabia, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 33
  • 3. 4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 374.4.2 Urine Analysis, Revenue (2004-2018) 414.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, Saudi Arabia, Company Share (2010-2011) 465 Genetic Testing In Saudi Arabia 485.1 Genetic Testing, Market Segmentation 485.2 Genetic Testing Market, Saudi Arabia, Revenue Mix ($m), 2011 495.3 Genetic Testing Market, Saudi Arabia, Segment Contribution (%), 2011 505.4 Genetic Testing Overall Revenue, (2004-2018) 515.5 Genetic Testing Distribution Share (2010-2011) 555.6 Genetic Testing, Saudi Arabia, Company Share (2010-2011) 566 Haematology In Saudi Arabia 586.1 Haematology Market, Market Segmentation 586.2 Haematology Market, Saudi Arabia, Revenue Mix ($m), 2011 596.3 Haematology Market, Saudi Arabia, Segment Contribution (%), 2011 606.4 Haematology Overall Revenue, (2004-2018) 616.4.1 Haematology Reagents, Revenue (2004-2018) 656.4.2 Immunohaematology, Revenue (2004-2018) 696.4.3 Haemostasis, Revenue (2004-2018) 736.4.4 Haematology Rapid Tests, Revenue (2004-2018) 776.4.5 Haematology Cell Counters, Revenue (2004-2018) 816.5 Haematology Distribution Share (2010-2011) 856.6 Haematology, Saudi Arabia, Company Share (2010-2011) 867 Histology And Cytology In Saudi Arabia 887.1 Histology and Cytology Market, Market Segmentation 887.2 Histology And Cytology Market, Saudi Arabia, Revenue Mix ($m), 2011 897.3 Histology And Cytology Market, Saudi Arabia, Segment Contribution (%), 2011 907.4 Histology And Cytology Overall Revenue, (2004-2018) 917.5 Histology And Cytology Distribution Share (2010-2011) 957.6 Histology And Cytology, Saudi Arabia, Company Share (2010-2011) 968 Immuno Chemistry In Saudi Arabia 988.1 Immuno Chemistry Market, Saudi Arabia, Revenue Mix ($m), 2011 988.2 Immuno Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 998.3 Immuno Chemistry Overall Revenue, (2004-2018) 1008.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 1048.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 1088.3.3 Endocrinology Tests, Revenue (2004-2018) 1128.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 1168.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 1208.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 1248.4 Immuno Chemistry Distribution Share (2010-2011) 1288.5 Immuno Chemistry, Saudi Arabia, Company Share (2010-2011) 129
  • 4. 9 Infectious Immunology In Saudi Arabia 1319.1 Infectious Immunology, Market Segmentation 1319.2 Infectious Immunology Market, Saudi Arabia, Revenue Mix ($m), 2011 1329.3 Infectious Immunology Market, Saudi Arabia, Segment Contribution (%), 2011 1339.4 Infectious Immunology Overall Revenue, (2004-2018) 1349.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 1389.5 Infectious Immunology Distribution Share (2010-2011) 1429.6 Infectious Immunology, Saudi Arabia, Company Share (2010-2011) 14310 Microbiology Culture In Saudi Arabia 14510.1 Microbiology Culture, Market Segmentation 14510.2 Microbiology Culture Market, Saudi Arabia, Revenue Mix ($m), 2011 14610.3 Microbiology Culture Market, Saudi Arabia, Segment Contribution (%), 2011 14710.4 Microbiology Culture Overall Revenue, (2004-2018) 14810.4.1 Microbiology Analyzers, Revenue (2004-2018) 15210.5 Microbiology Culture Distribution Share (2010-2011) 15610.6 Microbiology Culture, Saudi Arabia, Company Share (2010-2011) 15711 Overview of Key Companies in Saudi Arabia In Vitro Diagnostics Market 15911.1 F. Hoffmann-La Roche Ltd. 15911.1.1 Company Overview 15911.1.2 Share in the Saudi Arabia In Vitro Diagnostics Market 15911.2 Siemens Healthcare 16011.2.1 Company Overview 16011.2.2 Share in the Saudi Arabia In Vitro Diagnostics Market 16011.3 Abbott Laboratories 16111.3.1 Company Overview 16111.3.2 Share in the Saudi Arabia In Vitro Diagnostics Market 16111.4 Beckman Coulter, Inc. 16211.4.1 Company Overview 16211.4.2 Share in the United States In Vitro Diagnostics Market 16211.5 bioMerieux S.A. 16311.5.1 Company Overview 16311.5.2 Share in the Saudi Arabia In Vitro Diagnostics Market 16311.6 Becton, Dickinson and Company 16411.6.1 Company Overview 16411.6.2 Share in the Saudi Arabia In Vitro Diagnostics Market 16411.7 Ortho-Clinical Diagnostics Inc. 16511.7.1 Company Overview 16511.8 Mindray Medical International Limited 16511.8.1 Company Overview 16511.9 Bio-Rad Laboratories, Inc. 16611.9.1 Company Overview 16611.10 Sysmex Corporation 166
  • 5. 11.10.1 Company Overview 16611.11 Qiagen N.V. 16711.11.1 Company Overview 16711.12 Thermo Fisher Scientific Inc. 16711.12.1 Company Overview 16711.13 Grifols, S.A. 16811.13.1 Company Overview 16811.14 Horiba, Ltd. 16811.14.1 Company Overview 16811.15 PerkinElmer, Inc. 16911.15.1 Company Overview 16911.16 Life Technologies Corporation 16911.16.1 Company Overview 16911.17 Phadia AB 17011.17.1 Company Overview 17011.18 DiaSorin S.p.A 17011.18.1 Company Overview 17011.19 Gen-Probe Incorporated 17111.19.1 Company Overview 17111.20 Diagnostica Stago, Inc. 17111.20.1 Company Overview 17111.21 Chembio Diagnostics, Inc. 17211.21.1 Company Overview 17211.22 Alere Inc. 17211.22.1 Company Overview 17211.23 Immucor, Inc. 17311.23.1 Company Overview 17311.24 Hologic, Inc. 17311.24.1 Company Overview 17312 In Vitro Diagnostics Market Pipeline Products 17412.1 Clinical Chemisty Market Pipeline Products 17412.2 Immuno Chemistry Market Pipeline Products 17712.3 Haematology Market Pipeline Products 18812.4 Infectious Immunology Market Pipeline Products 19012.5 Microbiology Culture Market Pipeline Products 19712.6 Histology And Cytology Market Pipeline Products 19812.7 Genetic Testing Market Pipeline Products 19913 Financial Deals Landscape 20413.1 Partnerships 20413.1.1 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 20413.1.2 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 205
  • 6. 13.1.3 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 20613.1.4 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology Solutions 20713.1.5 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpressDx Test 20813.1.6 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology20913.1.7 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 21013.1.8 CML HealthCare Enters Into Agreement With MaRS Innovation 21113.1.9 Castle Biosciences Enters Into Licensing Agreement With Brigham and Womens HospitalFor Mesothelioma Test 21213.1.10 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 21313.1.11 GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 21413.1.12 NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For OncotypeDX Tests 21513.1.13 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TBTest 21613.1.14 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 21713.1.15 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 21813.1.16 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 21913.1.17 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus22013.1.18 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 22113.1.19 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POCTest 22213.1.20 One Lambda Enters Into Co-Marketing Agreement With CellTrend 22313.1.21 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics ForALK Cancer Biomarker 22413.1.22 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 22513.1.23 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker22613.1.24 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor CellTechnology 22713.1.25 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 22813.1.26 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRangePCR Kit 22913.1.27 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 23013.1.28 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
  • 7. Pressure Cycling Technology 23113.1.29 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 23213.1.30 GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 23313.1.31 NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 23413.1.32 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 23514 Appendix 23614.1 Definitions of Markets Covered in the Report 23714.1.1 In Vitro Diagnostics 23714.2 Research Methodology 24814.3 Secondary Research 24814.4 Primary Research 24914.5 Models 24914.6 Forecasts 25014.7 Expert Panels 25014.8 GlobalData Consulting 25014.9 Currency Conversion 25114.10 Contact Us 25114.11 Disclaimer 2511.1 List of TablesTable 1: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, 2004-2018 19Table 2: In Vitro Diagnostics Market, Saudi Arabia, Category Contribution (%), 2011 21Table 3: In Vitro Diagnostics Market, Saudi Arabia, Cross-Category Analysis, 2004-2018 23Table 4: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, Historic, 2004-2011 25Table 5: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, Forecast,2011-2018 27Table 6: In Vitro Diagnostics, Saudi Arabia, Company Share by Revenue ($m), USD Constant,2010-2011 29Table 7: Clinical Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 32Table 8: Clinical Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 34Table 9: Clinical Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 36Table 10: Clinical Chemisty Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 38Table 11: Clinical Chemisty Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 40Table 12: Urine Analysis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 42
  • 8. Table 13: Urine Analysis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 44Table 14: Clinical Chemistry, Saudi Arabia, Distribution Share by Revenue ($m), USD Constant,2010-2011 45Table 15: Clinical Chemistry, Saudi Arabia, Company Share by Revenue ($m), USD Constant,2010-2011 47Table 16: Genetic Testing Market, Saudi Arabia, Segment Contribution (%), 2011 50Table 17: Genetic Testing, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 52Table 18: Genetic Testing, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 54Table 19: Genetic Testing, Saudi Arabia, Distribution Share by Revenue ($m), USD Constant,2010-2011 55Table 20: Genetic Testing, Saudi Arabia, Company Share by Revenue ($m), USD Constant, 2010-2011 57Table 21: Haematology Market, Saudi Arabia, Segment Contribution (%), 2011 60Table 22: Haematology, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 62Table 23: Haematology, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 64Table 24: Haematology Reagents, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 66Table 25: Haematology Reagents, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 68Table 26: Immunohaematology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 70Table 27: Immunohaematology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 72Table 28: Haemostasis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 74Table 29: Haemostasis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 76Table 30: Haematology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 78Table 31: Haematology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 80Table 32: Haematology Cell Counters, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 33: Haematology Cell Counters, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 34: Haematology, Saudi Arabia, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
  • 9. Table 35: Haematology, Saudi Arabia, Company Share by Revenue ($m), USD Constant, 2010-2011 87Table 36: Histology And Cytology Market, Saudi Arabia, Segment Contribution (%), 2011 90Table 37: Histology And Cytology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 92Table 38: Histology And Cytology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 94Table 39: Histology And Cytology, Saudi Arabia, Distribution Share by Revenue ($m), USDConstant, 2010-2011 95Table 40: Histology And Cytology, Saudi Arabia, Company Share by Revenue ($m), USDConstant, 2010-2011 97Table 41: Immuno Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 99Table 42: Immuno Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 101Table 43: Immuno Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 103Table 44: Disease Specific Immunochemistry, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 105Table 45: Disease Specific Immunochemistry, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 107Table 46: Drugs of Abuse / Toxicology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 109Table 47: Drugs of Abuse / Toxicology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 111Table 48: Endocrinology Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 113Table 49: Endocrinology Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 115Table 50: Immunochemistry Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 117Table 51: Immunochemistry Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 119Table 52: Therapeutic Drug Monitoring, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 121Table 53: Therapeutic Drug Monitoring, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 123Table 54: Immunochemistry Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 125Table 55: Immunochemistry Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 127Table 56: Immuno Chemistry, Saudi Arabia, Distribution Share by Revenue ($m), USD Constant,2010-2011 128
  • 10. Table 57: Immuno Chemistry, Saudi Arabia, Company Share by Revenue ($m), USD Constant,2010-2011 130Table 58: Infectious Immunology Market, Saudi Arabia, Segment Contribution (%), 2011 133Table 59: Infectious Immunology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 135Table 60: Infectious Immunology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 137Table 61: Infectious Immunology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 139Table 62: Infectious Immunology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 141Table 63: Infectious Immunology, Saudi Arabia, Distribution Share by Revenue ($m), USDConstant, 2010-2011 142Table 64: Infectious Immunology, Saudi Arabia, Company Share by Revenue ($m), USDConstant, 2010-2011 144Table 65: Microbiology Culture Market, Saudi Arabia, Segment Contribution (%), 2011 147Table 66: Microbiology Culture, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 149Table 67: Microbiology Culture, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 151Table 68: Microbiology Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 153Table 69: Microbiology Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 155Table 70: Microbiology Culture, Saudi Arabia, Distribution Share by Revenue ($m), USD Constant,2010-2011 156Table 71: Microbiology Culture, Saudi Arabia, Company Share by Revenue ($m), USD Constant,2010-2011 158Table 72: Clinical Chemisty Market Pipeline Products 174Table 73: Immuno Chemistry Market Pipeline Products 177Table 74: Haematology Market Pipeline Products 188Table 75: Infectious Immunology Market Pipeline Products 190Table 76: Microbiology Culture Market Pipeline Products 197Table 77: Histology And Cytology Market Pipeline Products 198Table 78: Genetic Testing Market Pipeline Products 199Table 79: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 204Table 80: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 205Table 81: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 206Table 82: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology Solutions 207
  • 11. Table 83: Med BioGene Amends Licensing Agreement With Precision Therapeutics ForLungExpress Dx Test 208Table 84: Ovizio Imaging Systems Enters Into Distribution Agreement With ApplikonBiotechnology 209Table 85: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 210Table 86: CML HealthCare Enters Into Agreement With MaRS Innovation 211Table 87: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 212Table 88: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 213Table 89: GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 214Table 90: NewBridge Pharma Enters Into Licensing Agreement With Genomic Health ForOncotype DX Tests 215Table 91: Epistem Enters Into Distribution Agreement With Becton Dickinson For MycobacteriumTB Test 216Table 92: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 217Table 93: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 218Table 94: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test219Table 95: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus220Table 96: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 221Table 97: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4POC Test 222Table 98: One Lambda Enters Into Co-Marketing Agreement With CellTrend 223Table 99: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics ForALK Cancer Biomarker 224Table 100: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 225Table 101: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERGMarker 226Table 102: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating TumorCell Technology 227Table 103: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 228Table 104: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen ForLongRange PCR Kit 229Table 105: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 230Table 106: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 231Table 107: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 232Table 108: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
  • 12. Cyclotron And PET Tracer System 233Table 109: NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 234Table 110: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 2351.2 List of FiguresFigure 1: In Vitro Diagnostics, Market Segmentation 17Figure 2: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, 2004-2018 18Figure 3: In Vitro Diagnostics Market, Saudi Arabia, Revenue Mix ($m), 2011 20Figure 4: In Vitro Diagnostics Market, Saudi Arabia, Category Contribution (%), 2011 21Figure 5: In Vitro Diagnostics Market, Saudi Arabia, Cross-Category Analysis, 2004-2018 22Figure 6: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, Historic, 2004-2011 24Figure 7: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Constant, Forecast,2011-2018 26Figure 8: In Vitro Diagnostics, Saudi Arabia, Company Share (%), 2011 28Figure 9: Clinical Chemistry, Market Segmentation 30Figure 10: Clinical Chemistry Market, Saudi Arabia, Revenue Mix ($m), 2011 31Figure 11: Clinical Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 32Figure 12: Clinical Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 33Figure 13: Clinical Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 35Figure 14: Clinical Chemisty Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 37Figure 15: Clinical Chemisty Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 39Figure 16: Urine Analysis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 41Figure 17: Urine Analysis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 43Figure 18: Clinical Chemistry, Saudi Arabia, Company Share (%), 2011 46Figure 19: Genetic Testing, Market Segmentation 48Figure 20: Genetic Testing Market, Saudi Arabia, Revenue Mix ($m), 2011 49Figure 21: Genetic Testing Market, Saudi Arabia, Segment Contribution (%), 2011 50Figure 22: Genetic Testing, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 51Figure 23: Genetic Testing, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 53Figure 24: Genetic Testing, Saudi Arabia, Company Share (%), 2011 56Figure 25: Haematology Market, Market Segmentation 58Figure 26: Haematology Market, Saudi Arabia, Revenue Mix ($m), 2011 59
  • 13. Figure 27: Haematology Market, Saudi Arabia, Segment Contribution (%), 2011 60Figure 28: Haematology, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 61Figure 29: Haematology, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 63Figure 30: Haematology Reagents, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 65Figure 31: Haematology Reagents, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 67Figure 32: Immunohaematology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 69Figure 33: Immunohaematology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 71Figure 34: Haemostasis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 73Figure 35: Haemostasis, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 75Figure 36: Haematology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 77Figure 37: Haematology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 79Figure 38: Haematology Cell Counters, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 81Figure 39: Haematology Cell Counters, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 83Figure 40: Haematology, Saudi Arabia, Company Share (%), 2011 86Figure 41: Histology and Cytology Market, Market Segmentation 88Figure 42: Histology And Cytology Market, Saudi Arabia, Revenue Mix ($m), 2011 89Figure 43: Histology And Cytology Market, Saudi Arabia, Segment Contribution (%), 2011 90Figure 44: Histology And Cytology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 91Figure 45: Histology And Cytology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 93Figure 46: Histology And Cytology, Saudi Arabia, Company Share (%), 2011 96Figure 47: Immuno Chemistry Market, Saudi Arabia, Revenue Mix ($m), 2011 98Figure 48: Immuno Chemistry Market, Saudi Arabia, Segment Contribution (%), 2011 99Figure 49: Immuno Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 100Figure 50: Immuno Chemistry, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 102Figure 51: Disease Specific Immunochemistry, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 104
  • 14. Figure 52: Disease Specific Immunochemistry, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 106Figure 53: Drugs of Abuse / Toxicology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 108Figure 54: Drugs of Abuse / Toxicology, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 110Figure 55: Endocrinology Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 112Figure 56: Endocrinology Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 114Figure 57: Immunochemistry Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 116Figure 58: Immunochemistry Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 118Figure 59: Therapeutic Drug Monitoring, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 120Figure 60: Therapeutic Drug Monitoring, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 122Figure 61: Immunochemistry Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 124Figure 62: Immunochemistry Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 126Figure 63: Immuno Chemistry, Saudi Arabia, Company Share (%), 2011 129Figure 64: Infectious Immunology, Market Segmentation 131Figure 65: Infectious Immunology Market, Saudi Arabia, Revenue Mix ($m), 2011 132Figure 66: Infectious Immunology Market, Saudi Arabia, Segment Contribution (%), 2011 133Figure 67: Infectious Immunology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 134Figure 68: Infectious Immunology, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 136Figure 69: Infectious Immunology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 138Figure 70: Infectious Immunology Rapid Tests, Saudi Arabia, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 140Figure 71: Infectious Immunology, Saudi Arabia, Company Share (%), 2011 143Figure 72: Microbiology Culture, Market Segmentation 145Figure 73: Microbiology Culture Market, Saudi Arabia, Revenue Mix ($m), 2011 146Figure 74: Microbiology Culture Market, Saudi Arabia, Segment Contribution (%), 2011 147Figure 75: Microbiology Culture, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 148Figure 76: Microbiology Culture, Saudi Arabia, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 150
  • 15. Figure 77: Microbiology Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 152Figure 78: Microbiology Analyzers, Saudi Arabia, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 154Figure 79: Microbiology Culture, Saudi Arabia, Company Share (%), 2011 157Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Saudi Arabia In Vitro DiagnosticsMarket, 2011 159Figure 81: Siemens Healthcare, Company Share (%),Saudi Arabia In Vitro Diagnostics Market,2011 160Figure 82: Abbott Laboratories, Company Share (%),Saudi Arabia In Vitro Diagnostics Market,2011 161Figure 83: Beckman Coulter, Inc., Company Share (%),Saudi Arabia In Vitro Diagnostics Market,2011 162Figure 84: bioMerieux S.A., Company Share (%),Saudi Arabia In Vitro Diagnostics Market, 2011163Figure 85: Becton, Dickinson and Company, Company Share (%),Saudi Arabia In VitroDiagnostics Market, 2011 164Contact: sales@reportsandreports.com for more information.